Journal of Law, Medicine & Ethics 2008-01-01

Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?

Keith C Ferdinand

文献索引：J. Law. Med. Ethics 36(3) , 458-63, (2008)

全文：HTML全文

摘要

Race is not a scientific category, but African Americans have increased prevalence and severity of heart failure. The African American Heart Failure trial showed the benefit of a combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (an antioxidant). Future research may unmask the reason for cardiovascular differences in therapy.